A late-stage pharmaceutical company focusing on womens healthcare products.

We are very very happy to welcome representatives from prominent fresh investors to our table of directors and appreciate the continued solid support from our earlier investors. Their industry knowledge and encounter will greatly benefit Agile as we transition right into a ongoing company with marketed products. Related StoriesApplying a high restaurant model to health care communications: an interview with Brandi Robinson, SanofiAddressing standard of living needs in prostate cancer: an interview with Professor Louis DenisWABA calls for global action to aid women to combine breastfeeding and workDr. Rossi continuing, Agile is the only company advancing contraceptive patches based on the well-set up hormone, levonorgestrel, which has a 25 year protection background in the U.S.The first clinical study for GGF2 in sufferers with heart failing is expected to start in mid-2010.D., Ph.D., Vice President of Preclinical Development at Acorda. NHLBI, a division of the National Institutes of Health , provides C-TRIP grants to be able to advance research on promising fresh therapeutics that address unmet medical needs in cardiovascular diseases. The grant will support early phase GGF2 clinical research.